Dauricine is the major bioactive component isolated from the root of Dauricum D.C., which has shown promising pharmacological activities with a great potential for clinic use.
Introduction
Bisbenzylisoquinolines (BBIQ) are a large and diverse family of natural alkaloids found in many plants. The majority of naturally occurring BBIQ alkaloids are mainly identified from families of Menispermaceae, Ranunculaceae, Annonnaceae, and Moniaceae (Guha et al., 1979; Schiff, 1983; Schiff, 1987; Schiff, 1991) . Bisbenzylisoquinoline alkaloids have been reported to show varieties of pharmacological activities (Schiff, 1991) . Many herbs containing BBIQ alkaloids have been used as traditional medicines in many cultures in China, India, Japan, Chile, and in many other nations (Chang and Wu, 2005; Amresh et al., 2008; Martínez et al., 1997; Koh et al., 2006) . Dauricine (1, Scheme 1) is a bisbenzylisoquinoline alkaloid isolated from the root of Menispermum Dauricum DC (Li and Gong, 2007) . Dauricine has been reported to show multiple pharmacological actions, including decelerating transmembrane ion shift, inhibiting anoxic depolarization, and scavenging oxygen free radicals, all of which are likely to affect many of the interconnected pathological processed involved in apoptotic death (Jin et al., 2002) . Moreover, this agent has been used for the treatment of various diseases, such as cardiac ischemia, angina, and inflammation (Jin et al., 2002) .
Recently, we reported a dauricine-derived quinone methide metabolite, 2, (Scheme 1) in human liver microsomal incubations (Wang et al., 2009 ). The quinone methide metabolite was trapped with glutathione (GSH) to form the corresponding GSH conjugate, 3 (Scheme 1). The formation of quinone methide metabolite 2 required NADPH present in the incubation system, and the presence of ketoconazole suppressed the generation of the quinone methide intermediate. A selection of individual human recombinant cytochrome P450 was incubated with dauricine, and only CYP3A4 was found to be the P450 enzyme responsible for the formation of the quinone methide metabolite. The dauricine-derived GSH conjugate was also detected in bile from rats given dauricine (Wang et al., 2009) . We proposed that the quinone methide metabolite is formed via dehydrogenation mediated by CYP3A4 (Scheme 1).
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Quinone methides are well-known electrophilic species with high reactivity toward nucleophiles (Monks and Jones, 2002) . Numbers of quinone methide metabolites have been documented in metabolism studies of varieties of substances, such as butylated hydroxytoluene (BHT) (Monks and Jones, 2002) , p-cresol (Gaikwad and Bodell, 2001) , safrole (Monks and Jones, 2002) , phencyclidine (Driscoll et al., 2007) , troglitazone (Kassahun et al., 2001) , tamoxifen (Fan et al., 2000) , droloxifene (Yao et al., 2001) , and toremifene (Yao et al., 2001 ).
Quinone methide metabolites have been reported to covalently modify nuclear acids (Hecht et al., 2001 ) and proteins (Monks and Jones, 2002) , and the modification of the biomolecules was suggested to correlate toxicities of the quinone methide metabolites (Thompson et al., 2001 ).
Bioactivation of BHT derivatives has been extensively studied, and the reactivity of quinone methides derived from BHT derivatives appears to correlate with their pulmonary toxicity (Monks and Jones, 2002) . In this study, we report the pulmonary toxicity induced by dauricine in cultured cells and airways and in mice. In addition, we provide the evidence for the formation of a quinone methide metabolite in lung microsomal incubations with dauricine. This sounds an alarming note for the safe use of dauricine as a potential pharmaceutical agent.
Materials and methods

Chemicals and materials
Dauricine was purchased from Shenzhen Medherb Bio-Tech Co., Ltd (Shenzhen, China).
Ethidium homodimer-III (EthD-III) was purchased from Biotium (Hayward, CA), and 4'-6-diamidino-2-phenylindole (DAPI) purchased from Vector Laboratories (Burlingame, CA).
Ketoconazole, DNAse and formaldehyde solution were purchased from Sigma-Aldrich (St. Louis, Mo). Gentamicin, media DMEM/F12 and RPMI-1640, and trypsin were purchased from Mediatech (Herndon, VA). Medium LHC-9 was purchased from Invitrogen (Grand Island, NY). Hematoxyline and eosin were purchased from Fisher Scientific (Fair Lawn, NJ). Lowmelting-point agarose and D-luciferin were purchased from Promega (Madison, WI). 4-JPET #162297
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Ipomeanol was kindly provided from National Cancer Institute (Frederick, MD). Dauricinederived GSH conjugate 3 was synthesized according to the procedure we recently reported (Wang et al., 2009) . Recombinant P450 enzymes CYP1A1, CYP2B6, and CYP3A5 were purchased from BD Gentest (Woburn, MA).
Animals and treatment
Male CD-1 mice (20 -22 g) were obtained from Charles River Laboratories (Wilmington, MA) and had free access to water and food. Stock solutions of dauricine were prepared as follows. Dauricine (18.0 mg) was suspended in 0.5 mL water, and the resulting suspension was acidified by adding dilute HCI solution until dauricine was dissolved. The resultant solution was neutralized with dilute NaOH solution, followed by addition of water to appropriate concentrations. For the toxicity test of dauricine, the animals were divided into 4 groups, and each group contained six mice. One group was administered intraperitoneally with saline as vehicle control, and the other groups were treated with dauricine at dosages of 50 mg/kg, 100 mg/kg, and 150 mg/kg, respectively. The animals were sacrificed 24 hr after the administration.
Following anesthesia with pentobarbital, blood was harvested by cardiac puncture for AST, ALT and BUN assays. In a separated study, mice were administered i.p. with ketoconazole (50 mg/kg). After 1.5 hr of the pretreatment, the animals were given i.p. dauricine at 150 mg/kg and sacrificed 24 hr after the treatment.
Bronchoalveolar lavage (BAL) fluid collection
Mice were anesthetized, and the trachea was exposed and cannulated with a feeding needle tied in place. The lungs were perfused with PBS via right ventricle into the pulmonary artery to remove blood from the lungs. The lungs were lavaged with PBS buffer (0.8 mL × 2).
The recovered fluids were centrifuged at 1500 × g for 15 min at 4°C. The supernatants were collected for the measurement of lactate dehydrogenase (LDH) activity.
ALT, AST and BUN assays
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The blood samples collected above were allowed to clot in test tubes at room temperature overnight, followed by centrifuging at 3,000 rpm. The resulting sera were collected for ALT, AST and BUN assays. Serum ALT and AST activities were measured by following manufacturer's instruction (Catachem Inc, Bridgeport, CT). BUN was assessed by use of QuantiChrom TM urea assay kit (Bioassay Systems, Hayward, CA).
BAL fluid LDH activity and protein assays
The activity of LDH in BAL fluids harvested was measured by In Vitro Toxicology Assay kit from Sigma-Aldrich (St. Louis, Mo). Specific activity was based on protein concentrations as determined using BCA protein assay kit (Pierce Inc., Rockford, IL).
Histopathological analysis
The lung tissues were fixed in 10% neutral buffered formalin, paraffin processed, and sectioned at 3 µm. For histological analysis, the tissue sections were stained with hematoxylin and eosin (H&E).
Cell permeability
The evaluation of lung cell membrane integrity was conducted according to the method developed by Van Winkle and coworkers (Van et al., 1999; Phimister et al., 2005) 
Micro-dissection of airway segments and culture
Micro-dissection of airway segment and tissue culture were performed as described by van Winkle and coworkers (Van et al., 1996) . Briefly, animals were anesthetized with pentobarbital, and the lungs were inflated with 1% low-melting agarose gel. The lung tissues were immersed in DMEM/F12 medium during dissection. The distal airway branches were dissected starting from their branchpoint with the major daughter airway to the most distal terminal bronchioles. The resulting dissected lung airways were gently washed with PBS buffer to remove agarose possibly remaining within the tissues and then incubated with 4-ipomeanol or dauricine in serum free DMEM/F12 medium supplemented with gentamicin (50 μg/ml). After 24 hr incubation the media were harvested for LDH assay, and the airways were homogenized, and the lysates were collected for protein assay.
Preparation of primary pulmonary cells
Primary pulmonary cells were prepared by following the protocol described by Kim and coworkers (Kim et al., 2005) . Briefly, mice were anesthetized and lungs were perfused with 10 mL PBS buffer, followed by intra-tracheal instillation with 1.0 mL 1% low-melting agarose. The 
Cell-based CYP3A assays
CYP3A assays were performed using a P450-Glo™ luciferin-PFBE assay kit (Promega, Madison, WI), according to the manufacturer's protocol. Briefly, cells were seeded (1×10 PFBE substrate agent. After 4 hr incubation at 37°C, an aliquot (50 μL) of the resulting medium was mixed with luciferin detection reagent (50 μL) in a well of a 96-well opaque white luminometer plate. The mixture was incubated at room temperature for 20 min, and luminescence was read in VICTOR TM3 Multilabel Plate Counters (PerkinElmer, Boston, MA).
Product concentrations were determined based on a standard curve prepared in parallel using authentic standard D-luciferin.
Cell culture and cytotoxicity assay
Human pulmonary cell lines WI-38, BEAS-2B and A549 were incubated in media DMEM/F12, LHC-9, and RPMI-1640, respectively, supplemented with 10% FBS and gentamicin (50 µg/mL). Cells were seeded in 96-well plates at a density of 1×10 4 /well and exposed to dauricine at designed concentrations. The resulting cells were cultured at 37°C in a humidified incubator with 95% air/5% CO 2 . The cell viability was determined using CellTiter 96 Aqueous (Promega, Madison, WI) based on the protocol provided by the manufacturer.
Mouse lung microsome preparation and incubation
Mouse lung microsomal fractions were prepared by differential centrifugation based on the procedure reported by Watt and coworkers (Watt et al., 1999) and stored in portions at -80°C until used. The mouse lung microsomes were carefully thawed on ice prior to the experiments. Dauricine (10 μM) was individually mixed with the lung microsomes (1.0 mg protein/mL) in 100 mM potassium phosphate buffer (pH 7.4) supplemented with GSH at final concentration of 5 mM. The total incubation volume was 200 μL. After 3 min of preincubation at 37°C, the incubation reactions were initiated by the addition of NADPH (1.0 mM). After 60 min incubation, the reactions were terminated with equal volume of ice-cold acetonitrile. In a separated incubation, ketoconazole (10 μM) was incorporated prior to the addition of NADPH.
Control samples containing no NADPH were included. Each incubation was performed in duplicates. Protein of the incubation samples was precipitated by addition of 400 μL methanol.
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The mixture was vortexed and centrifuged at 11,000 g for 5 min. The supernatant was transferred into a glass tube, evaporated to dryness under a stream of nitrogen at 40ºC and then reconstituted in 100 μL of methanol with 5 mM ammonium acetate (30:70, v/v) . A 20 μL-aliquot of the reconstituted solution was injected to LC/MS n for analysis.
Human recombinant cytochromes P450 incubation
Human recombinant P450 enzymes (supersomes), including CYPs 1A1, 2B6 and 3A5, were carefully thawed on ice prior to the experiment. Dauricine (10 μM) was mixed with the individual human P450 enzymes (50 nM) in 200 μL of 100 mM potassium phosphate buffer (pH 7.4) supplemented with GSH at final concentration of 5 mM. After 3 min of preincubation at 37°C, the incubation reactions were initiated by addition of NADPH (1.0 mM). After 60 min incubation, the reactions were terminated with equal volume of ice-cold acetonitrile. The proteins in the samples were precipitated, and the supernatant was harvested for mass spectrometry analysis as described above. Each incubation was performed in duplicates.
Kinetic study
Dauricine (1-200 μ M) was incubated with recombinant CYP3A5 enzyme (50 nM) in 100 mM potassium phosphate buffer (pH 7.4). The reaction mixtures (200 μL) containing GSH (5 mM) were preincubated at 37°C for 3 min, and then the reaction was initiated by addition of NADPH (final concentration: 1.0 mM) and was terminated with equal volume of ice-cold acetonitrile after 60 min incubation. The resulting GSH conjugate was assessed by LC/MS n . All data points represent the means of duplicate estimations. K m and V max values were determined by nonlinear least-squares regression analysis using SigmaPlot software (SPSS Inc., Chicago, IL).
Mass spectrometry instrumentation
The mass spectrometry analyses were carried out on an Agilent 1200 HPLC system coupled with a 6330 LC/MSD Trap XCT Ultra (Agilent Technologies, Waldbronn, Germany).
This article has not been copyedited and formatted. The final version may differ from this version. (Phenomenex, Torrance, CA, USA). The mobile phase was a gradient of a mixture of (A) methanol and (B) 5 mM ammonium acetate programmed as follows: initial 20% A maintained for 5 min, then increased to 30% in 0.5 min, maintained at 30% for 10 min, then increased to 40% in 0.5 min, maintained at 40% for 5 min, then increased to 60% in 0.5 min, maintained at 60%
for 5 min and finally decreased to 20% A in 0.5 min, maintained at 20% A for 10 min. The flow rate was 0.6 mL/min and the injection volume was 20 μL. The HPLC effluent going to the mass spectrometer was directed to waste through a divert valve for the initial 5 min after sample μL of methanol and the precipitate removed by centrifugation at 3,000 rpm for 5 min. The supernatants were dried as described above, reconstituted in 200 μL of methanol with 5 mM ammonium acetate (30:70, v/v) , and subjected to LC-MS analysis.
Data analysis
All results are given as means ± SE. The results were analyzed by Student's t-test (GraphPad software, San Diego, CA). A value of p < 0.05 was considered significant (*), and p < 0.01 was highly significant (**) compared to the corresponding control.
Results
LDH activity in BAL fluids
To evaluate the pulmonary toxicity by dauricine, LDH activity in BAL fluids was monitored at 24 hr after administration of dauricine. As shown in Figure 1A , intraperitoneal administration of dauricine produced a dose-dependent increased LDH activity in BAL fluids and about 3-fold elevation of LDH activity in BAL fluids in animals at 150 mg/kg.
Permeability and histology
To image the pulmonary injury by dauricine at a tissue/cell level, the lungs were stained with EthD-III and DAPI. Remarkable ethidium-positive (shown in red in Figure 1B ) cells were observed in the lungs obtained from the animals treated with dauricine at the dose of 150 mg/kg, while lungs of the control animals showed no detectable ethidium-labeled cells. The ethidium labeling of lung cells exhibited dose-dependency of lung injury after intraperitoneal exposure to dauricine ( Figure 1B ). To examine lung toxicity induced by dauricine the histopathologic changes of the lungs of mice were also monitored. Alveolar edema along with hemorrhage was observed in the animals given dauricine at dose of 150 mg/kg ( Figure 1C ).
Distal airway incubation
This article has not been copyedited and formatted. The final version may differ from this version. To examine the toxic effect of dauricine on distal airway tissues, distal airways were dissected, harvested, and incubated with dauricine, followed by monitoring LDH released to the media. About 2-fold increase in LDH activity was observed in the media where the microdissected airway tissues were exposed to dauricine at concentration of 100 µM for 24 hr ( Figure   2 ). Unlike dauricine, 4-ipomeanol at the same molar concentration only produced mild increase in LDH activity in the media relative to the control group (Figure 2 ).
Cell culture
Human lung WI-38 cells were exposed to dauricine at concentrations of 5, 10, 20 and 40 µM, and cell viability was examined 24 hr after the exposure. About 40% cell death was observed after exposure to dauricine at 20 µM, and exposure to 40 µM of dauricine caused more than 60% cell death ( Figure 3A) . The same studies were performed in BEAS-2B and A549 cell lines, and similar observed toxicity was obtained (Supplemental Figure 1) . In a separated study, WI-38 cells were incubated with dauricine at concentration of 40 µM, and cell viability was monitored at 0, 2, 4, 8, 16 and 24 hr following the exposure. As shown in Figure   3B , significant cell death started at 8 hr after the exposure to dauricine, and the cell death continued with the exposure time. To ensure that cell lines BEAS-2B, WI-38, and A549 express CYP3A at an appropriate level, we compared cellular CYP3A activity of the cell lines with that of mouse lung primary cells. All the cell lines showed CYP3A activity with a similar level as that in mouse lung primary cells (Table 1) .
Protective effect of ketoconazole
Dauricine was administered in mice pretreated with ketoconazole or vehicle, followed by examining LDH activity in BAL fluids 24 hr post administration. As expected, the exposure of 4). Histopathologic evaluation study also revealed the similar protective effect of ketoconazole on dauricine-induced pulmonary toxicity. As shown in Figure 1C , the pretreatment of ketoconazole substantially reduced alveolar edema and hemorrhage induced by dauricine.
Bioactivation of dauricine in mouse lung microsomes
In our earlier metabolism studies, quinone methide metabolite 2 (Scheme 1) was trapped by glutathione in human liver microsomal incubations. Glutathione conjugate 3 (Scheme 1) was characterized by mass spectrometry and NMR spectroscope (Wang et al., 2009) . A similar metabolism study was performed to ensure that the same quinone methide metabolite is formed from dauricine in the incubations with mouse lung microsomes. Dauricine was incubated with lung microsomes in the presence or absence of NADPH, and the resulting electrophilic metabolites were trapped with glutathione, followed by LC/MS n analysis. As expected, a peak monitored at m/z 930 responsible for GSH conjugate 3 was observed in samples from the incubations in the presence of NADPH ( Figure 5B ), while no such peak was detected in the samples from the NADPH-absent incubations ( Figure 5A ). The retention time (10.4 min) of the peak was the same as that of the synthetic GSH conjugate 3 ( Figure 5D ). The effect of ketoconazole on the bioactivation of dauricine was examined, and the presence of ketoconazole (10 μM) in lung microsomal incubations caused substantial suppression (42.7% based on peak areas) of quinone methide metabolite (2) formation as shown in Figure 5C . Figure 6 shows MS/MS spectra of authentic GSH conjugate 3 and the one detected in the microsomal incubations. As expected, the multiple-stage mass spectra of GSH conjugate 3 detected in the microsomal incubations were found to be identical with authentic GSH conjugate 3 we chemically synthesized ( Figure 6 ).
Bioactivation of dauricine in human recombinant P450 enzymes
We tested the activity of human recombinant CYPs 1A1, 2B6 and 3A5 in biotransformation of dauricine to quinone methide 2, and CYP3A5 was the only one found to catalyze the formation of the quinone methide trapped by GSH. The apparent K m and V max for the formation of dauricine-derived quinone methide in recombinant CYP3A5 incubations were determined, and they were 17.0 μM and 8.03 pmol/min/nmol CYP3A5, respectively. Table 2 lists the values of parameters K m , V max , and V max /K m obtained from the enzyme kinetic studies.
The corresponding biochemical parameters for CYP3A4 are adopted from our earlier work (Wang et al., 2009 ).
Tissue distribution of dauricine
We monitored the distribution of the parent alkaloid in the liver, lung and kidney in mice given dauricine. Dauricine was found in the all organ tissues examined, but no huge difference in its distribution abundance was observed among the liver, lung and kidney. The alkaloid reached the liver faster than the lung and kidney, while it stayed longer in the lung and kidney than in the liver (Figure 7 ).
Discussion
This current study reports that acute exposure of bisbenzylisoquinoline dauricine produced pulmonary toxicity in CD-1 mice. In earlier studies, we found that dauricine was biotransformed to quinone methide metabolite 2 in human liver microsomal incubations (Wang et al., 2009 ). The quinone methide metabolite was trapped by glutathione and characterized by mass spectrometry and NMR. Quinone methides are known electrophilic species, and it has been speculated that quinone methides have a great potential to induce varieties of toxicities.
The present toxicity study was started by our earlier finding of quinone methide metabolite 2 along with the knowledge about toxic significance of quinone methides. As an initial step, we examined toxic effects of dauricine on liver, kidney and lung in CD-1 mice. The hepatotoxicity was assessed by monitoring serum AST and ALT activity; the nephrotoxicity was monitored by determining serum BUN; and the pneumotoxicity was evaluated by examining LDH activity in treatment at all doses (data not shown). However, the administration of dauricine was found to produce an elevation of LDH activity in BAL fluids, and the elevated LDH activity in BAL fluids was dose-dependent ( Figure 1A ).
We further examined the histopathologic changes of lung tissues obtained from mice treated with dauricine. As expected, significant pulmonary lesions were observed, including intra-alveolar edema, and hemorrhage ( Figure 1C ). Furthermore, we imaged the respiratory injury at a tissue/cell level by use of a staining technique which is based on the assessment of cell membrane integrity by ethidium homodimer-III permeability and fluorescence microscopy.
The ethidium homodimer-based cell permeability evaluation provided us a semi-quantitative assay to assess pulmonary cell lesions. The dye successfully stained the lung cells which lost integrity of cell membrane in animals given dauricine. The injured cells permeable to ethidium homodimer-III were proportional to the doses of dauricine administered in animals ( Figure 1B ).
This provides quantitative histopathologic evidence for the toxic effect of dauricine on the pulmonary system.
4-Ipomeanol is a prototype for potent selective pulmonary toxin. Boyd and coworkers reported that 4-ipomeanol caused morphological damage in lungs at dose of 30 mg (0.20 mmol)/kg (Michael, 1977) , and we found dauricine that produced detectable lung injury at 0.16 mmol (100 mg)/kg. We also compared the pulmonary toxicity induced by 4-ipomeanol and dauricine by incubation of micro-dissected mouse airways with the individual toxins. At concentration of 100 μM, 4-ipomeanol caused mild elevation of LDH activity in the media, whereas at the same concentration, dauricine caused 2-fold increases relative to the vehicletreated group. This indicates that dauricine is more toxic than 4-ipomeanol, a model agent of pulmonary toxin.
In previous study, we identified quinone methide metabolite 2 in human liver microsomal incubations with dauricine (Wang et al., 2009 ). We speculated possible involvement of the quinone methide metabolite of dauricine in the lung injury induced by dauricine. Similar study was performed to seek quinone methide metabolites of dauricine using mouse lung microsomes.
As expected, quinone methide 2 was trapped by co-incubated glutathione, and the resulting GSH conjugate 3 (Scheme 1) was detected by LC/MS n ( Figures 5 and 6 ), implicating that dauricine can be bioactivated not only in the liver but also in lung tissues. The observed requirement of NADPH for the formation of the quinone methide metabolite provided the evidence for the metabolism-dependency of biochemical activation of dauricine.
In early studies, we tested the catalytic role of human liver P450 enzymes, including CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, in the formation of quinone methide metabolites of dauricine and found only CYP3A4 is the one responsible for the metabolic activation of dauricine (Wang et al., 2009 ). The composition of human lung P450
enzymes is a little different from that in human liver, and the major P450 enzymes in human lung include CYPs1A1, 2A6, 2B6, 2E1, and 3A4/3A5 (Zhang et al., 2006) . We examined the catalytic activity of human recombinant CYPs1A1, 2B6 and 3A5, in addition to CYPs2A6, 2E1, and 3A4 we had tested earlier (Wang et al., 2009) , to transform dauricine to quinone methide metabolite 2. Among the three CYP enzymes tested, only CYP3A5 showed catalysis for the formation of the quinone methide. As expected, quinone methide 2, existing as GSH conjugate 3, was detected by LC-MS.
CYP3A subfamily is one of the major P450 proteins in human lung (Zhang et al., 2006 ).
Anttila and co-workers reported that CYP3A5 is the dominant CYP3A protein in human pulmonary system relative to CYP3A4 (Anttila et al., 1997) . In our earlier and current studies, we examined the catalytic activity of a total of ten human recombinant CYP enzymes, including CYPs1A1, 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4 and 3A5, to bioactivate dauricine. We found that only CYPs3A4 and 3A5 showed enzymatic activity for the formation of quinone methide metabolite 2. However, CYP3A5 showed much lower affinity (7-fold lower in K m )
This article has not been copyedited and formatted. The final version may differ from this version. was as much as 33 times larger than that by CYP3A5 (Table 2) . We believe that CYP3A4 most likely dominates the bioactivation of dauricine in human lungs regardless its significantly lower expression than that of CYP3A5 in human respiratory system (Anttila et al., 1997) .
Ketoconazole is a known CYP3A inhibitor. Co-incubation of ketoconazole was found to suppress the bioactivation of dauricine in the mouse lung microsomal incubations (Figure 4 ).
This encouraged us to investigate the role of CYP3A in the pulmonary toxicity induced by dauricine in mice. We compared the pulmonary toxicity of the alkaloid in mice with or without pretreatment with ketoconazole. As expected, we found that the animals pretreated with ketoconazole are significantly less susceptible to dauricine than those pre-administered with vehicle ( Figures 1C and 4) . The observed protective effect of ketoconazole on pulmonary toxicity by dauricine, along with the fact that ketoconazole suppressed the formation of quinone methide 2 in lung microsomal incubations with dauricine, implicates the involvement of metabolic activation of dauricine in the pulmonary toxicity induced by dauricine. However, the mechanistic role of the quinone methide metabolite in toxicity of dauricine is under investigation.
We tested whether dauricine causes cytotoxicity in human lung cell lines. Three cell lines, including BEAS-2B, WI-38 and A549, were tested, and these are representatives of lung bronchus, lung fibroblast, and lung cancer cell lines, respectively. These cell lines were found to express similar levels of CYP3A enzymes as that expressed by mouse primary lung cells (Table 1) . Dauricine showed a concentration-and time-dependency of cytotoxic effect on the human cell lines tested. More than 60% of cell death was observed in the human lung cell lines after exposure to dauricine at concentration of 40 μM in 24 hr. This raises the safety issue to use dauricine and related bisbenzylisoquinolines as potential pharmaceutical agents.
This article has not been copyedited and formatted. The final version may differ from this version. Like many other pulmonary toxicants such as 4-ipomeanol, naphthalene, and 3-methylindole, the mechanisms of the observed selective pulmonary toxicity of dauricine remain unknown. We monitored the distribution of dauricine in mice, and no enrichment of dauricine was observed in the lung tissues, although dauricine was eliminated more slowly from the lung than the liver. The susceptibility of pulmonary system to acute dauricine toxicity unlikely results from relatively slow elimination of the alkaloid from lung tissues. One explanation for the liver resistance to acute dauricine toxicity may include the higher capacity of hepatic glutathione against the attack by the quinone methide metabolite, in spite of the fact that CYP3A is concentrated highest in liver tissues. Similarly, less expression of glutathione S-transferases in pulmonary system than liver tissues may also contribute the susceptibility of lung tissues to dauricine toxicity.
In summary, our present studies first showed that dauricine selectively causes acute pulmonary toxicity in mice. The alkaloid was also found to induce cytotoxicity in representative human lung cell lines. Pretreatment with ketoconazole protected mice from dauricine-induced pulmonary injury. Dauricine was metabolized to the corresponding quinone methide metabolite that reacts with GSH. The CYP3A subfamily is responsible for catalyzing the formation of the electrophilic quinone methide metabolite. However, whether pulmonary toxicity induced by dauricine correlates the quinone methide metabolite of dauricine needs to be further investigated. Changes in LDH released to media in cultured micro-dissected lung airways after exposure to 4-ipomeanol (IPO, 100 μM) and dauricine (DAU, 100 μM). Data represent three independent experiments (means ± SEM, *<P 0.05 vs. IPO). Table 2 Values of apparent kinetic parameters K m , V max and K m /V max obtained from incubations of dauricine with human recombinant CYP3A4 or CYP3A5 in the presence of NADPH and GSH. GSH conjugate 3 was monitored by LC-
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The kinetic data of CYP3A4 are adopted from our early work (Wang et al., 2009 
